International journal of molecular sciencesOct 27, 2026

Targeting multiple pathways beyond single GLP-1 drugs for precise treatment and lasting change in childhood obesity

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 28, 2026

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists have markedly improved treatment efficacy for childhood obesity but have limitations.

Childhood obesity is influenced by various factors, including genetics, hormonal signaling, and environmental exposure.
Current treatments based on GLP-1 receptor agonism may lead to heterogeneous responses and weight recurrence after withdrawal.
Precision pharmacotherapy could involve combinations of treatments such as GLP-1/glucagon co-agonism, GIP/GLP-1, and FGF21 analogues.
Genotype-directed and lesion-directed treatments show promise in correcting causal pathways for specific obesity types.
Treatment selection for common obesity should consider individual factors like developmental stage, body composition, and insulin resistance.
Monitoring should encompass growth, psychosocial well-being, and overall health to evaluate disease modification and treatment effectiveness.

Simplified

Childhood obesity is a heterogeneous chronic disease shaped by genetic susceptibility, neuroendocrine signaling, energy homeostasis, adipose dysfunction, insulin resistance, and environmental exposure. Glucagon-like peptide-1 (GLP-1) receptor agonists have markedly improved treatment efficacy, but heterogeneous response, weight recurrence after withdrawal, residual organ risk, and limited long-term pediatric data expose the limitations of a single-pathway, weight-centered model. This narrative review integrates the molecular rationale and clinical evidence for precision pharmacotherapy beyond single GLP-1 receptor agonism. It examines glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 and GLP-1/glucagon co-agonism, triple agonism, amylin combinations, fibroblast growth factor 21 (FGF21) analogues, leptin replacement, and melanocortin-4 receptor (MC4R) agonism, separating established pediatric evidence from adult proof-of-concept and preclinical inference. Genotype-directed treatment for monogenic and syndromic obesity and lesion-directed treatment for acquired hypothalamic obesity provide the clearest examples of causal pathway correction. For common obesity, treatment selection should integrate developmental stage, hyperphagia, insulin resistance, ectopic fat, body composition, genetic context, treatment burden, and early response. Disease modification should be evaluated across growth, puberty, bone and lean tissue, beta cell and hepatic health, physical function, psychosocial well-being, safety, and durability. A dynamic cycle of phenotyping, mechanism-based treatment, multidomain monitoring, adaptation, and longitudinal re-phenotyping may improve the clinical relevance of pediatric obesity care.

Full Text

Full text is available at the source.

View Full Text ↗

Targeting multiple pathways beyond single GLP-1 drugs for precise treatment and lasting change in childhood obesity

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief